论文部分内容阅读
目的探讨分析f-PSA与t-PSA的比值对前列腺增生的诊断价值。方法 2009年6月-2012年6月间在我院进行治疗70例前列腺癌患者和75例前列腺增生患者,采用酶免疫标记法测定f-PSA与t-PSA值,计算F/T比值。结果两组患者的t-PSA与F/T值均有显著差异。按照不同浓度t-PSA范围进行分组比较,当t-PSA<4ug/L时,两组患者T-PSA无显著差异(P>0.05),但F/T均值有显著差异(P<0.05)。当t-PSA介于4ug/L-10ug/L时,两组患者t-PSA无显著差异(P>0.05),但F/T比值有极其显著差异(P<0.01)。当t-PSA>10ug/L时,两组患者t-PSA存在显著差异(P<0.05),F/T比值也存在显著差异(P<0.05)。结论 F/T比值对于前列腺癌的诊断价值较t-PSA更高。
Objective To investigate the diagnostic value of the ratio of f-PSA to t-PSA for benign prostatic hyperplasia. Methods From June 2009 to June 2012, 70 patients with prostate cancer and 75 patients with benign prostatic hyperplasia were treated in our hospital. F-PSA and t-PSA values were measured by enzyme-linked immunosorbent assay and the F / T ratio was calculated. Results There was a significant difference in t-PSA and F / T between the two groups. There was no significant difference in T-PSA between the two groups when t-PSA <4 ug / L, but the F / T mean was significantly different (P <0.05). There was no significant difference in t-PSA between the two groups when t-PSA ranged from 4ug / L to 10ug / L (P> 0.05), but the F / T ratio was significantly different (P <0.01). When t-PSA> 10 ug / L, there was a significant difference in t-PSA between the two groups (P <0.05) and a significant difference in F / T ratio (P <0.05). Conclusion The diagnostic value of F / T ratio for prostate cancer is higher than t-PSA.